‘Antithrombotic Drugs Market Worth $26.4bn In 2021’ Says Visiongain Report

15 August 2018
Pharma

Visiongain’s new report Antithrombotic Drugs Market 2017 – 2027: Anticoagulants, Antiplatelets, Fibrinolytics indicates that the antithrombotic drugs market will see $26.4bn in spending in 2021.

The revenue of the antithrombotic drugs market in 2016 is estimated at $18.08bn and is expected to grow at a CAGR of 7.9% in the first half of the forecast period. The anticoagulants segment accounted for the largest share of the market in 2016, this segment held 58.5% of the antithrombotic drugs market.
The lead analyst of this report said: “The risk of thrombosis increases with age, thus the prevalence of this group of diseases is increasing with the aging population of the developed world. Additionally, obesity and immobility are also significant risk factors for thrombotic disease.
This increasing demand for antithrombotic drug treatment combined with the high profile severity of thrombotic disease means there is a constant demand for drugs with improved safety, efficacy and administration. R&D activity has resulted in the launch of several novel drugs in recent years such as the direct thrombin inhibitor Pradaxa and the factor Xa inhibitors Xarelto and Eliquis, and more recently, Zontivity and Lixiana/Savaysa. In a market where generic drugs are major competitors in terms of volume of sales, these novel drugs are significant growth drivers.”
The 186-page report contains 84 tables and 69 figures that add visual analysis in order to explain the developing trends within the Antithrombotic Drugs Market.
Visiongain provides revenue forecasts for the period 2017-2027 as well as qualitative analyses for the antithrombotic drugs market and its leading submarkets: Anticoagulants, Antiplatelets, Fibrinolytics.
The 186-page report offers market forecasts for the leading drugs in this market, including: Direct factor Xa inhibitors, Heparins, Direct thrombin inhibitors, Vitamin K antagonists, Xarelto, Plavix, Lovenox, Eliquis, Pradaxa, Activase, Brilinta/Brilique, Aspirin Cardio, Effient, Aggrenox/Asasantin, Fragmin, Pletal, Angiomax/Angiox.
This report provides discussion on pipeline products in various stages of clinical trials and regulatory approval.
Our work discusses the leading companies in the antithrombotic drugs market. Our study also discusses the SWOT and STEP analysis of the antithrombotic drugs market. Moreover, our report provides revenue forecast for the leading regional and national market: the US, Japan, EU5 (the UK, Germany, France, Spain, and Italy), BRIC (Brazil, Russia, India, and China) and RoW.

The report Antithrombotic Drugs Market 2017 – 2027: Anticoagulants, Antiplatelets, Fibrinolytics report will be of value to anyone who wants to better understand the antithrombotic drugs market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the antithrombotic drugs market.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.

Visiongain publishes reports produced by its analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

Read

“Global somatostatin analogs market is anticipated to grow at a lucrative CAGR of 5.3% and anticipated to reach USD 4.78 Bn by 2029”, says Visiongain report.

Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.

05 September 2019

Read